Abstract
Invasive fungal diseases (IFD) are associated with considerable morbidity and mortality in patients with hematological malignancies. Primary antifungal prophylaxis (PAP) is effective for decreasing incidence of IFD, and the patients will be more tolerable to chemotherapy with less cost and better prognosis. Antifungal drugs as fluconazole, itraconazole, posaconazole, caspofungin and micafungin are all recommended for PAP by many consensus and guidelines. The PAP will be more scientific, appropriate and effective with the development of studies about predicting risk-stratification for IFD, new drugs, pharmacokinetics and integrated prophylaxis. This review summarizes the progress of PAP in hematological malignancy patients in recent years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
